Skip to main navigation
Skip to search
Skip to main content
Oregon Health & Science University Home
Help & FAQ
Home
Profiles
Research units
Core Facilities
Publications
Search by expertise, name or affiliation
Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial
Arise Investigators
Neurology
Research output
:
Contribution to journal
›
Article
›
peer-review
69
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
ABBV-8E12
21%
Accidental Falls
13%
Antibodies
4%
Canada
7%
Double-Blind Method
8%
France
7%
Germany
7%
Intention
7%
Italy
7%
Japan
6%
Least-Squares Analysis
9%
Medical Futility
23%
Monoclonal Antibodies
6%
Neurodegenerative Diseases
7%
Passive Immunization
10%
Pharmaceutical Preparations
10%
Placebos
51%
Population
3%
Progressive Supranuclear Palsy
100%
Random Allocation
16%
Randomized Controlled Trials
50%
Research Personnel
5%
Safety
43%
Spain
8%
tau Proteins
10%
Technology
5%
Therapeutics
9%